靶向制剂治疗类风湿关节炎的研究进展  

Recent Advances in Targeted Agents for the Treatment of Rheumatoid Arthritis

作　　者：苏慧 李成 SU Hui;LI Cheng(College of Pharmacy, Yanbian University, Yanji 133000,China;Department of Pharmacy, Affiliated Hospital of Yanbian University, Yanji 133000,China)

机构地区：[1]延边大学药学院,延吉133000 [2]延边大学附属医院药学部,延吉133000

出　　处：《医药导报》2020年第12期1672-1676,共5页Herald of Medicine

基　　金：国家自然科学基金资助项目(81660619)。

摘　　要：类风湿关节炎(RA)是一种多关节慢性自身免疫性疾病。表现为严重的软骨破坏和大量炎症细胞浸润,最终诱发全身并发症、残疾,使生活质量下降。目前临床治疗RA的药物存在剂量大、给药频繁、不良反应严重等缺点。这些局限性极大地促进了靶向制剂在RA治疗中的研究和应用。该文综述了靶向药物治疗RA的不良反应研究进展,讨论各种靶向策略的应用,阐明需要解决的挑战和对未来的展望。Rheumatoid arthritis(RA)is a multi-joint chronic autoimmune disease.It is characterized by severe cartilage destruction and a large amount of inflammatory infiltration,which induce systemic complications and disability and eventually reduce the quality of life.Currently,the drugs used for the treatment of RA have several disadvantages,such as large dosage,frequent administration and serious side effects.These limitations have greatly promoted the research and application of targeted drugs in RA therapy.In this article,we review the recent progress of targeted drugs in the treatment of RA and discuss the application of various targeting strategies.Finally,the challenges needed to be solved and outlook for the futurewas discussed.

关 键 词：靶向制剂 类风湿关节炎 自身免疫性疾病 纳米技术 

分 类 号：R97[医药卫生—药品] R593.22[医药卫生—药学]